Hot Features
Premium
Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 9,896 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Addex Therapeutics Ltd | ADXN | NASDAQ | Depository Receipt |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -2.63 | -14.03% | 16.11 | 14:22:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.81 | 15.09 | 16.89 | 18.74 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 213 | 9,896 | 16.17 | 160,051 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:18:39 | 200 | 16.11 | USD |
Addex Therapeutics Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 232.94M | 77.13M | - | 1.42M | -20.8M | -0.27 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Addex Therapeutics
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
ADXN Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe. |
